<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H22441B46B49043AEAD45D5EE451AB236" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>111 HR 1488 IH: Affordable Insulin Now Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1488</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230309">March 9, 2023</action-date><action-desc><sponsor name-id="C001119">Ms. Craig</sponsor> (for herself, <cosponsor name-id="K000380">Mr. Kildee</cosponsor>, and <cosponsor name-id="M001208">Mrs. McBath</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committees on <committee-name committee-id="HWM00">Ways and Means</committee-name>, and <committee-name committee-id="HED00">Education and the Workforce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XXVII of the Public Health Service Act, the Internal Revenue Code of 1986, and the Employee Retirement Income Security Act of 1974 to establish requirements with respect to cost-sharing for certain insulin products, and for other purposes.</official-title></form><legis-body id="HEB4074CE17A042F2B2D1175B2D9433CB" style="OLC"><section id="H2636F0DD09384C6BBBF5B3F49563E515" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Affordable Insulin Now Act</short-title></quote>.</text></section><section id="HB0183FE239F94F329565F26481A26BB9"><enum>2.</enum><header>Requirements with respect to cost-sharing for insulin products</header><subsection id="H073EBC9D26DC4EA7973DD82E9F7683C2"><enum>(a)</enum><header>PHSA</header><text display-inline="yes-display-inline">Part D of title XXVII of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-111">42 U.S.C. 300gg–111 et seq.</external-xref>) is amended by adding at the end the following new section:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H4EFD284D768F4283806B85BB60E8BD0A"><section id="H5AA1E72E4A0C4A8B82A0DCA9BE6D7FE4"><enum>2799A–11.</enum><header>Requirements with respect to cost-sharing for certain insulin products</header><subsection id="H08C5E67EF5084666A9496D686114FE75"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">For plan years beginning on or after January 1, 2024, a group health plan or health insurance issuer offering group or individual health insurance coverage shall provide coverage of selected insulin products, and with respect to such products, shall not—</text><paragraph id="H2FB0E0399A9A447DB203EB0C1766985B"><enum>(1)</enum><text>apply any deductible; or</text></paragraph><paragraph id="H4C20FC1566AC414DBD03014B110DC4F5"><enum>(2)</enum><text>impose any cost-sharing in excess of the lesser of, per 30-day supply—</text><subparagraph id="H6BDD307C5E254D2A9D10CC56BF8AFC05"><enum>(A)</enum><text>$35; or</text></subparagraph><subparagraph id="H49897844E6594332A705AEFF0B5F37A6"><enum>(B)</enum><text>the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan or coverage, including price concessions received by or on behalf of third-party entities providing services to the plan or coverage, such as pharmacy benefit management services.</text></subparagraph></paragraph></subsection><subsection id="H49391A600C6F4B8AB6FDCBD7A0ED4536"><enum>(b)</enum><header>Definitions</header><text>In this section:</text><paragraph id="HB58DB463ACEC48CE8AB09EA0E666CA00"><enum>(1)</enum><header>Selected insulin products</header><text>The term <term>selected insulin products</term> means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan or health insurance issuer.</text></paragraph><paragraph id="H362BA7931BEF4B1B865D969904C99B7A"><enum>(2)</enum><header>Insulin defined</header><text>The term <term>insulin</term> means insulin that is licensed under subsection (a) or (k) of section 351 and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 and continues to be marketed pursuant to such licensure. </text></paragraph></subsection><subsection id="HD5313B71ACB7482293B7107D815FE90D"><enum>(c)</enum><header>Out-of-Network providers</header><text>Nothing in this section requires a plan or issuer that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan or issuer that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider.</text></subsection><subsection id="H8DE997677B844B09B8138D29FE62B2F7"><enum>(d)</enum><header>Rule of construction</header><text>Subsection (a) shall not be construed to require coverage of, or prevent a group health plan or health insurance coverage from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law.</text></subsection><subsection commented="no" id="HBB84E4C23FDB4D8D8D8E1422B711DB42"><enum>(e)</enum><header>Application of cost-Sharing towards deductibles and out-of-Pocket maximums</header><text>Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan or coverage.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HC93CB1853DE3497FB7A0F56468F38DF2"><enum>(b)</enum><header>IRC</header><paragraph id="HF1DC4F61DA1949B9A6CD0F164DDCF051"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subchapter B of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/100">chapter 100</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HEC2A9AE598FC428196B4408A45AFC21A"><section id="HC5588AD52B4644279A3180D672DA1BC7"><enum>9826.</enum><header>Requirements with respect to cost-sharing for certain insulin products</header><subsection id="HFF34CE0CB4F043C78CEEF0507D5BAAFF"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">For plan years beginning on or after January 1, 2024, a group health plan shall provide coverage of selected insulin products, and with respect to such products, shall not—</text><paragraph id="H6F3A016B0F3449298AECF83701030AD0"><enum>(1)</enum><text>apply any deductible; or</text></paragraph><paragraph id="HA8912921F309483798EC451DA4CD27E1"><enum>(2)</enum><text>impose any cost-sharing in excess of the lesser of, per 30-day supply—</text><subparagraph id="H3FD89AACC4A7456DBCED060B5FF586F2"><enum>(A)</enum><text>$35; or</text></subparagraph><subparagraph id="H9A2EE2BAF7E7419A86EC3EB70ACED1AA"><enum>(B)</enum><text>the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan, including price concessions received by or on behalf of third-party entities providing services to the plan, such as pharmacy benefit management services.</text></subparagraph></paragraph></subsection><subsection id="H09EDF1836DFD4EA388779EDFE827F2DC"><enum>(b)</enum><header>Definitions</header><text>In this section:</text><paragraph id="HD9FD9A0B0B5A4E7AB89A6BF54FC0F3C8"><enum>(1)</enum><header>Selected insulin products</header><text>The term <term>selected insulin products</term> means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan.</text></paragraph><paragraph id="H7A4188F3B5C444959CED1D39698F1DF0"><enum>(2)</enum><header>Insulin defined</header><text>The term <term>insulin</term> means insulin that is licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) and continues to be marketed pursuant to such licensure. </text></paragraph></subsection><subsection id="H4D26F1FEB376425E831DB7127C7A8804"><enum>(c)</enum><header>Out-of-Network providers</header><text>Nothing in this section requires a plan that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider.</text></subsection><subsection id="HB6DE1681882C4D2983BA0A50142293CC"><enum>(d)</enum><header>Rule of construction</header><text>Subsection (a) shall not be construed to require coverage of, or prevent a group health plan from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law.</text></subsection><subsection id="HCE7197A1B909425B888CB95604A86BD5" commented="no"><enum>(e)</enum><header>Application of cost-Sharing towards deductibles and out-of-Pocket maximums</header><text>Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H2E77E8770EC949DCA6494778EDB98F32"><enum>(2)</enum><header>Clerical amendment</header><text>The table of sections for subchapter B of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/100">chapter 100</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:</text><quoted-block display-inline="no-display-inline" id="H1C79192FBB36426BAEA91AB9F094942E" style="OLC"><toc regeneration="no-regeneration"><toc-entry level="section">Sec. 9826. Requirements with respect to cost-sharing for certain insulin products.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H563A14179D6841F0970057BA16A1B39E" display-inline="no-display-inline"><enum>(c)</enum><header>ERISA</header><paragraph id="H4384C8B1E53E4059B79A8AD66631A09D"><enum>(1)</enum><header>In general</header><text>Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 (<external-xref legal-doc="usc" parsable-cite="usc/29/1185">29 U.S.C. 1185 et seq.</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H2F935E610BB54119B6E2FEE60503E87E"><section id="H0D5677C3B0414C98AF91AADF6E1550ED"><enum>726.</enum><header>Requirements with respect to cost-sharing for certain insulin products</header><subsection id="H2422E51AE2224265A94320DC9B519D20"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">For plan years beginning on or after January 1, 2024, a group health plan or health insurance issuer offering group health insurance coverage shall provide coverage of selected insulin products, and with respect to such products, shall not—</text><paragraph id="H8F22F96C8F72442CA313D5C8F057111A"><enum>(1)</enum><text>apply any deductible; or</text></paragraph><paragraph id="H8F90B1DCF9E74AAEAE2E0F19AEAD1748"><enum>(2)</enum><text>impose any cost-sharing in excess of the lesser of, per 30-day supply—</text><subparagraph id="HFC4BEBE665F94DDF8514AB77355449BC"><enum>(A)</enum><text>$35; or</text></subparagraph><subparagraph id="H5DFE4FF34FCB4AE5A39285387BC20062"><enum>(B)</enum><text>the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan or coverage, including price concessions received by or on behalf of third-party entities providing services to the plan or coverage, such as pharmacy benefit management services.</text></subparagraph></paragraph></subsection><subsection id="H5C299E1BE813488BB40C9782FD3C79D3"><enum>(b)</enum><header>Definitions</header><text>In this section:</text><paragraph id="HF8127593153C42AEB635662DD513F39A"><enum>(1)</enum><header>Selected insulin products</header><text>The term <term>selected insulin products</term> means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan or health insurance issuer.</text></paragraph><paragraph id="HA4259D64C627443BAD40CC40A22DDDC4"><enum>(2)</enum><header>Insulin defined</header><text>The term <term>insulin</term> means insulin that is licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) and continues to be marketed pursuant to such licensure. </text></paragraph></subsection><subsection id="H5892068475E043F7815DC8F4F2EB06AA"><enum>(c)</enum><header>Out-of-Network providers</header><text>Nothing in this section requires a plan or issuer that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan or issuer that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider.</text></subsection><subsection id="H831AEAC48030458195A5A4DDFE5AE0C5"><enum>(d)</enum><header>Rule of construction</header><text>Subsection (a) shall not be construed to require coverage of, or prevent a group health plan or health insurance coverage from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law.</text></subsection><subsection commented="no" id="HC112597CE50245B1B3F515D44D8BAFF8"><enum>(e)</enum><header>Application of cost-Sharing towards deductibles and out-of-Pocket maximums</header><text>Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan or coverage.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H5BC88576C92143789346FED4F0C65CF6"><enum>(2)</enum><header>Clerical amendment</header><text>The table of contents in section 1 of the Employee Retirement Income Security Act of 1974 (<external-xref legal-doc="usc" parsable-cite="usc/29/1001">29 U.S.C. 1001 et seq.</external-xref>) is amended by inserting after the item relating to section 725 the following:</text><quoted-block display-inline="no-display-inline" id="HCBC58E464AC04351AC3E37743FA02307" style="OLC"><toc regeneration="no-regeneration"><toc-entry level="section">Sec. 726. Requirements with respect to cost-sharing for certain insulin products.</toc-entry></toc><after-quoted-block>. </after-quoted-block></quoted-block></paragraph></subsection><subsection id="HAA7A7F372FE842AB8F4DC232D8947B41"><enum>(d)</enum><header>No effect on other cost-Sharing</header><text>Section 1302(d)(2) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/42/18022">42 U.S.C. 18022(d)(2)</external-xref>) is amended by adding at the end the following new subparagraph:</text><quoted-block style="OLC" id="H1C00EE730FC445A6B4BE78D624B107E3" display-inline="no-display-inline"><subparagraph id="HB6F1E0FAE2E04AC3A6AC24A40FAD0A65"><enum>(D)</enum><header>Special rule relating to insulin coverage</header><text display-inline="yes-display-inline">The exemption of coverage of selected insulin products (as defined in section 2799A–11(b) of the Public Health Service Act) from the application of any deductible pursuant to section 2799A–11(a)(1) of such Act, section 726(a)(1) of the Employee Retirement Income Security Act of 1974, or <external-xref legal-doc="usc" parsable-cite="usc/26/9826">section 9826(a)(1)</external-xref> of the Internal Revenue Code of 1986 shall not be considered when determining the actuarial value of a qualified health plan under this subsection.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H76E4D97D931541068DCFEFE84BDCA045"><enum>(e)</enum><header>Coverage of certain insulin products under catastrophic plans</header><text>Section 1302(e) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/42/18022">42 U.S.C. 18022(e)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HAC473914F0124402B0D726071106C3E1"><paragraph id="H89CA0A2E9580469B9F13040143F9C929"><enum>(4)</enum><header>Coverage of certain insulin products</header><subparagraph id="H2EF4A888D9C94E64964503FF20D0197D"><enum>(A)</enum><header>In general</header><text>Notwithstanding paragraph (1)(B)(i), a health plan described in paragraph (1) shall provide coverage of selected insulin products, in accordance with section 2799A–11 of the Public Health Service Act, for a plan year before an enrolled individual has incurred cost-sharing expenses in an amount equal to the annual limitation in effect under subsection (c)(1) for the plan year.</text></subparagraph><subparagraph id="H6179FEEA154C48BD87BE790280D2EE8F"><enum>(B)</enum><header>Terminology</header><text>For purposes of subparagraph (A)—</text><clause id="H12392B76538B461B94122421D42F9D57"><enum>(i)</enum><text>the term <term>selected insulin products</term> has the meaning given such term in section 2799A–11(b) of the Public Health Service Act; and</text></clause><clause id="H0E6032F725664678A1C5EFDFD45CD561"><enum>(ii)</enum><text>the requirements of section 2799A–11 of such Act shall be applied by deeming each reference in such section to <quote>individual health insurance coverage</quote> to be a reference to a plan described in paragraph (1). </text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill> 

